Can Psychiatric Nurse Practitioners Prescribe Testosterone For Depression?

Viewing This Video Is A Member Exclusive Feature

But you don’t need membership to get Dr. O’Connor’s insight on this topic, it’s in the summary, key takeaways, and related drugs and conditions below.

Want to watch the full video? Join the Health Portal Today.

Join Now

Already a member? Sign In

Timeline

01:00

A psychiatric nurse practitioner asks about helping patients find competent testosterone providers and whether psychiatric clinicians can appropriately evaluate and prescribe testosterone.

02:30

Dr. O’Connor explains that published evidence supports testosterone as a potential treatment for depressive symptoms in selected men with hypogonadism or low-normal testosterone while emphasizing individualized care and regulatory considerations.

04:00

Dr. O’Connor discusses research involving testosterone gel and depression and recommends presenting testosterone as conservative, evidence-based therapeutic care and harm reduction rather than anti-aging treatment.

Video Summary

A psychiatric nurse practitioner asks whether testosterone can be prescribed to men with depression and low testosterone. Dr. O’Connor explains that published evidence supports a potential antidepressant benefit from testosterone replacement in selected men with hypogonadism or low-normal testosterone, while emphasizing that treatment decisions must be individualized and supported by symptoms, laboratory findings, and careful clinical evaluation.

The discussion focuses on how a psychiatric provider can approach testosterone prescribing from both a regulatory and clinical standpoint. Dr. O’Connor recommends using published therapeutic evidence, avoiding an anti-aging framework, and presenting testosterone as evidence-based treatment and harm reduction while maintaining a strong provider-patient relationship.

Testosterone is not presented as a simple antidepressant solution because it can suppress endogenous testosterone production and may worsen anxiety or moodiness in susceptible patients. Dr. O’Connor also emphasizes broader monitoring for cardiovascular and blood-related risks, including thrombotic complications, so psychiatric improvement is considered alongside the complete health effects of long-term testosterone therapy.

Drug Callouts

Testosterone

Testosterone is discussed as a potential treatment for depressive symptoms in men with hypogonadism or low-normal testosterone. Dr. O’Connor explains that some evidence supports psychiatric benefit while cautioning that testosterone can suppress endogenous production and may worsen anxiety or moodiness in susceptible men.

AndroGel

AndroGel is discussed while Dr. O’Connor describes published research evaluating testosterone gel in men with low testosterone and depressive symptoms. He uses this evidence to show why psychiatric clinicians considering testosterone should rely on therapeutic clinical data rather than anti-aging claims.

Condition Callouts

Depression

Depression is the primary psychiatric condition discussed in relation to testosterone treatment. Dr. O’Connor explains that selected men with low testosterone and depressive symptoms may improve with TRT, but psychiatric symptoms, testosterone status, and the broader clinical picture must be evaluated individually.

Hypogonadism

Hypogonadism is discussed as an important clinical context for considering testosterone in men with depressive symptoms. Dr. O’Connor emphasizes that symptomatic men may require individualized evaluation rather than assuming treatment decisions should depend solely on an extremely low total testosterone number.

Anxiety

Dr. O’Connor cautions that testosterone may worsen anxiety or moodiness in some susceptible men even when treatment is being considered for depressive symptoms. This makes psychiatric monitoring especially important when TRT is prescribed to men who already have mental health concerns.

Deep Vein Thrombosis

Deep vein thrombosis is discussed among the serious vascular complications clinicians should consider when monitoring men receiving testosterone. Dr. O’Connor emphasizes that psychiatric benefits must be weighed alongside blood-related and cardiovascular risks during long-term TRT.

Pulmonary Embolism

Pulmonary embolism is identified as another serious thrombotic complication relevant to testosterone monitoring. Dr. O’Connor includes clotting risk within the broader health considerations that psychiatric clinicians must understand if they prescribe TRT.

Key Takeaways

Published evidence supports considering testosterone for depressive symptoms in selected men who also have hypogonadism or low testosterone.
Psychiatric clinicians considering testosterone should base treatment on symptoms, hormone measurements, published evidence, and individualized clinical evaluation.
Testosterone may improve depression in some men while worsening anxiety or moodiness in others, making psychiatric monitoring essential.
Testosterone prescribing should be framed as evidence-based therapeutic care and harm reduction rather than anti-aging treatment.
Clinicians prescribing testosterone for psychiatric patients must also consider endogenous suppression, cardiovascular health, and potential thrombotic complications.